Basiliximab (Synonyms: CHI 621) |
| Katalog-Nr.GC66331 |
Basiliximab (CHI 621) ist ein rekombinanter chimÄrer muriner/humaner monoklonaler IgG1-Anti-Interleukin-2-Rezeptor-AntikÖrper. Basiliximab kann fÜr die Erforschung der Nierentransplantation verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 179045-86-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation[1].
Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα[1].
Basiliximab binds only to activated lymphocytes and macrophages/monocytes[3].
Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα[3].
Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats[2].
| Animal Model: | Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia[2] |
| Dosage: | 0.07 mg/rat |
| Administration: | IV infusion, once |
| Result: | Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *